Apelix’s price advantage highlights new breast cancer treatment drug

Alpelisib (Alpelisib), an innovative breast cancer treatment drug, brings hope to specific patient groups with its unique PI3K inhibition mechanism. As a PI3K inhibitor, Apelvis can precisely inhibit the activity of PI3Kα (PIK3CA), thereby blocking the PI3K/AKT/mTOR signaling pathway that is abnormally activated in various cancers. This pathway is closely linked to the growth, proliferation and survival of tumor cells.

Apelvis has shown excellent results in the treatment of hormone receptor-positive, human epidermal growth factor receptor2-negative advanced or metastatic breast cancer, especially for patients who carry PIK3CA mutations and are resistant to endocrine therapy. Apelvis has shown significant therapeutic effects. Its excellent efficacy has been verified in multiple clinical trials. These trial data strongly prove that Apelvis can significantly extend the progression-free survival of patients and significantly improve their quality of life.

Although the original drug of Apelvis is not currently on the market in China and is therefore not covered by medical insurance, its price advantage in overseas markets has been highlighted. Specifically, the European version of Apelvis contains 56 tablets of 150mg per box, and the price may be as high as more than 40,000 yuan; in comparison, the Indian version is more user-friendly, with 28 tablets per box of 150mg priced at about 5,000 yuan. This price difference provides patients with more choices.

Generic drugs of Apelvis have also appeared in overseas markets, and these drugs are highly similar in ingredients to the original drugs. For example, the generic Apelvis drug produced by a well-known pharmaceutical factory in Laos has a specification of 150mg*28 tablets per box, and its price is as low as more than 2,000 yuan. Such a price advantage will undoubtedly further promote the popularity and application of Apelvis around the world.